ImmuneOnco’s IMM2510 and IMM27M Achieve Milestones in Phase I Clinical Trials
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd (HKG: 1541) has announced the completion of patient enrollment for...
Multi-specific antibodies
Janssen’s Rybrevant Combo Meets Primary Endpoint in Advanced NSCLC Study
Janssen, a subsidiary of Johnson & Johnson (J&J; NYSE: JNJ), has released an update on...
Bristol-Myers Squibb Acquires Rights to Zenas BioPharma’s Obexelimab for Autoimmune Diseases
US pharmaceutical major Bristol-Myers Squibb (BMS; NYSE: BMY) has entered into a licensing and cooperation...
Shanghai Junshi Biosciences’ JS207 Bispecific Antibody Receives NMPA Clinical Trial Approval
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...
United Laboratories’ UBT251 Receives Tacit Approval for Obesity Clinical Study in China
Hong Kong-based United Laboratories International Holdings Ltd (HKG: 3933) has announced that its Category 1...
Janssen Submits Rybrevant for FDA Review as First-Line NSCLC Treatment
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has submitted an additional indication for review...
Akeso Biopharma’s Ivonescimab Heads for Priority Review for NSCLC Treatment
China-based Akeso Biopharma (HKG: 9926) has announced that its bispecific antibody (BsAb) ivonescimab (AK112), targeting...
European Commission Grants Conditional Approval for Janssen’s Talvey in Multiple Myeloma
The European Commission (EC) has granted conditional approval to Johnson & Johnson’s (J&J; NYSE: JNJ)...
J&J’s Teclistamab Granted Priority Review in China for Relapsed Multiple Myeloma
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson’s (J&J, NYSE:...
CSPC Pharmaceutical Group Receives FDA Approval for NBL-028 Bispecific Antibody Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received the green...
Gilead Sciences Enters Collaboration with Tentarix Biotherapeutics for Polyspecific Antibodies
Gilead Sciences (NASDAQ: GILD) has announced the initiation of three collaboration programs with US-based Tentarix...
Pfizer’s Elrexfio Earns Accelerated FDA Approval for Relapsed/Refractory Multiple Myeloma
This week, Pfizer (NYSE: PFE) received an accelerated approval from the US Food and Drug...
Janssen’s Talvey Receives FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) announced last week that it...
BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448
China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND)...
RemeGen’s Novel Bispecific Antibody RC148 Receives Clinical Trial Approval
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has announced that it has received clinical trial...
Akeso Biopharma Reports First Positive Earnings in H1 2023 Financial Results
Akeso Biopharma (HKG: 9926) has released its financial report for the first half of 2023,...
Zelgen Biopharmaceuticals’ ZG006 Earns NMPA Approval for Clinical Trials in Solid Tumors
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a China-based biopharmaceutical company, has announced that it...
Nanjing Leads Biolabs’ LBL-034 Secures Clinical Trial Approvals from NMPA and FDA
Nanjing Leads Biolabs Co., Ltd, a China-based biopharmaceutical company, has announced receiving clinical trial approvals...
Akeso Biopharma Initiates Phase Ia/Ib Study for TIGIT mAb AK127 in Solid Tumors Combination Therapy
China-based Akeso Biopharma (HKG: 9926) has announced the first patient enrollment in a Phase Ia/Ib...
Boehringer Ingelheim Gets NMPA Approval for Phase II Study of BI 764532 in SCLC
Boehringer Ingelheim (BI) has announced that it has received approval from the National Medical Products...